Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bionorica Steers U.S. Consumers To Natural Products Through Science

This article was originally published in The Tan Sheet

Executive Summary

Natural product marketer Bionorica looks to science to convince parents about the efficacy of natural remedies for children while they become more aware of possible risks associated with OTC cough and cold formulas

You may also be interested in...



Pediatric Cough/Cold “Reverse Switch” Will Not Increase Safety – CHPA

A potential "reverse switch" of pediatric cough/cold OTC drugs to prescription status would not address concerns about efficacy or misuse of the products, the Consumer Healthcare Products Association says

Refillable Personal-Care Packaging: Experts Discuss Contamination Risks, Liability, MoCRA Compliance

Personal-care companies navigating a growing patchwork of state recycling laws are exploring refillable packaging options, but there are serious concerns and questions to consider before embarking down this potentially risky path, experts said at IBA’s Supply Chain & Sustainability Conference.

FDA’s Bumpus Will Be Principal Deputy Commissioner; Cosmetics Industry Reacts With Congratulations, Questions

Chief scientist Namandjé Bumpus will replace Janet Woodcock as principal deputy commissioner at the US FDA when the latter steps down in early 2024. The Personal Care Products Council says Bumpus will continue to lead MoCRA implementation efforts while a new chief scientist is sought, but those and other details remain fuzzy.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102790

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel